Kunal Dhamesha, Pharma & Healthcare Research Analyst at Macquarie Capital estimates a mid-teens EBITDA hit for Max Healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results